Introduction
============

Colon cancer is one of the most common malignant tumors, with a high incident rate in the 40--50 age group. Colon cancer affects \~150,000 patients in the USA annually ([@b1-mmr-16-05-6499]). Due to the changing of diets, colon cancer has become the 4th cause for malignant tumor mortality in China and there are \~140,000 diagnosed cases annually ([@b2-mmr-16-05-6499]). Surgery is the primary therapy for colon cancer and patients exhibit 5-year survival rate of 50% following surgery ([@b3-mmr-16-05-6499]).

However, 15--20% patients experience recurrence following treatment. Tumor recurrence following curative surgery is a major hindrance for the improvement of overall survival ([@b4-mmr-16-05-6499]). Therefore, it is important to identify the molecular changes in patients and to determine the underlying reason for colon cancer recurrence. Biomarkers have been used as tools in the detection and management of the disease in patients with colon cancer ([@b5-mmr-16-05-6499]). For instance, the CpG island methylator phenotype is independently associated with an unfavorable prognosis in patients with colon cancer ([@b6-mmr-16-05-6499]). Epithelial cell adhesion molecule, cluster of differentiation (CD)26, musashi RNA binding protein 1, CD29, CD24, leucine rich repeat containing G protein-coupled receptor 5 and aldehyde dehydrogenase 1 family member A1 have been identified as potential putative markers for colon cancer ([@b7-mmr-16-05-6499],[@b8-mmr-16-05-6499]). DNA methylation may also predict recurrence of resected stage III proximal colon cancer ([@b9-mmr-16-05-6499]). MicroRNA-93 inhibited the early relapse of colon cancer by targeting cell cycle-associated genes ([@b10-mmr-16-05-6499]). Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a mutation in colorectal cancer may act as a predictive molecular biomarker for adjuvant aspirin therapy in colon cancer ([@b11-mmr-16-05-6499]).

An improved understanding of the biology of recurrence may improve the development of novel recurrence prevention or treatment methods in colon cancer. In order to investigate the recurrence-associated genes in colon cancer for future therapy, a co-expression network of differentially expressed genes (DEGs) in colon cancer was constructed in the present study and the most significant modules in the network were used to reveal the recurrence-associated genes. Subsequently, the functions of recurrence-associated genes were enriched to determine the importance of these genes in the relapse of patients with colon cancer.

Materials and methods
=====================

### Microarray profiles

Two microarray profiles of colon cancer samples including recurrence information (E-GEOD-39,582 and E-GEOD-33,113) were downloaded from ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>). E-GEOD-39,582 included 566 samples, based on the platform of AFFY HG-U133_Plus_2, which were divided into the training dataset and the validation dataset for the weighted correlation network analysis (WGCNA) network construction. There were a total of 90 colon cancer samples in E-GEOD-33,113, with the recurrence status and clinical information of the samples, which was used as the validation dataset for mining vital module associated with recurrence.

### Sample classification

Samples in the profiles were classified using Consensus Clustering in R (<http://www.bioconductor.org/packages/release/bioc/html/ConsensusClusterPlus.html>) to identify their sub-types. The parameters set in this analysis are presented in [Table I](#tI-mmr-16-05-6499){ref-type="table"}. Following the classification of samples, the association between colon cancer samples and corresponding clinical performance \[survival, sex, cghdata, chemotherapy, mismatch repair (Mmr) status, tumor node metastasis (TNM) stage, and Tumor location\] were determiend using the χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

### Pretreatment of genes expression data

Data in the profiles were initially normalized using the robust multi-array analysis (RMA) method in Affy package (<http://www.bioconductor.org/packages/release/bioc/html/affy.html>) and were transformed using a log~2~ transformation. Probes were converted into gene symbols and the average expression value was used as the only value of the gene with multiple corresponding probes. Following that, the cv method in the genefilter package was applied to filter the genes with significant variation. Genes with coefficient of variation \>0.4 were recognized as the candidate genes.

### Screening of DEGs

The limma package in R (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>) was used to identify the DEGs from the candidate genes. P\<0.01 and log fold change (FC) \>1.5 were set as the cut-off criteria.

### Construction of the WGCNA co-expression network

The WGCNA method ([@b12-mmr-16-05-6499]) was used to construct the co-expression network of the genes in the test samples of colon cancer. The interaction coefficient between genes was calculated using the following formula:
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Where x~i~ and x~j~ are the expression vectors of gene i and j, respectively. The Pearson coefficient of these two vectors was cor, which was transited into the interaction coefficient using S~ij~. This transition intended to give more weight to the strong connections and reduce the importance of the weak connections in the predicted co-expression network in order to improve the reliability of the co-expression network.

The connection coefficient will be transformed into a weighted coefficient W~ij~ using the following formula:
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Subsequently, the co-expression network would be constructed based on the W matrix, followed by module mining. The reliability of the minded modules was verified using the verify sample set E-GEOD-33113. The topological properties were also confirmed. Modules with module significance \<0.05 were identified to be recurrence-associated modules.

### Verification of recurrence-associated modules

The average expression value of genes in the significant modules in each sample was calculated. Subsequently, the samples were ranked based on the expression level of modules. According to 1/4 and 3/4 value of expression level, the modules were divided into high expression level, median expression level, and low expression level. Finally, the Kaplan-Meier (KM) curves of recurrence-associated modules expression level and recurrence status were drawn. The significance of the different expression level modules was compared, and P\<0.05 was considered to indicate a statistically significant difference. The identified vital module was verified using the independent dataset E-GEOD-33113.

### Function enrichment of recurrence associated modules

In order to determine the functions of the genes in the recurrence-associated modules, genes were subjected to Database for Annotation, Visualization and Integrated Discovery ([@b13-mmr-16-05-6499]) for function and pathway enrichment. P\<0.05 was the threshold used for the significant terms.

### Survival analysis of genes in recurrence-associated modules

Survival analysis was performed on the genes in the recurrence-associated modules. The degree (k) of a gene and the significance (P) between each gene and sample survival time were also calculated using a Cox regression. Subsequently, the interaction coefficient (coef) between k and -log~10~(P) was computed to identify the hub genes associated with survival. Finally, selected genes were determined in the verifed samples for an association with survival. Recurrence associated genes were also subject to sample classification.

Results
=======

### Data preprocessing and sample classification

From the 19,846 irredundant genes in E-GEOD-39582, 6,600 were the variation genes. Consensus Clustering analysis revealed that cumulative distribution function (CDF) was at a high level when there were 3 sub-types, accompanied with a satisfied classification effect ([Fig. 1](#f1-mmr-16-05-6499){ref-type="fig"}). Therefore, the 556 samples in E-GEOD-39582 were divided into 3 subgroups: G1, G2, and G3 ([Fig. 2](#f2-mmr-16-05-6499){ref-type="fig"}). There were significant survival differences among these 3 types of samples, and as depicted in [Fig. 3](#f3-mmr-16-05-6499){ref-type="fig"}, G1 exhibited the highest survival status, whereas G3 exhibited the lowest survival status. Additionally, the c^2^ test determined that all clinical data, with the exception of sex, were significantly different among these 3 groups ([Table II](#tII-mmr-16-05-6499){ref-type="table"}).

### DEGs among the 3 sub-groups

From the 434 DEGs, 76 were the DEGs between G1 and G2, 390 were the DEGs between G1 and G3 and 63 were DEGs between G2 and G3. A total of 2 DEGs were identified in all 3 groups ([Fig. 4](#f4-mmr-16-05-6499){ref-type="fig"}). These two common DEGs were stress-associated endoplasmic reticulum protein family member 2 (SERP2) and long non-coding RNA-0219 (LINC0219).

### Co-expression network construction and module mining

The co-expression network of the training dataset was divided into 4 modules ([Fig. 5](#f5-mmr-16-05-6499){ref-type="fig"}), which were verified with the validation dataset. By calculating the correlation coefficient, the connections between the genes in each module and survival status of the samples were identified. It was determined that the Brown module had the highest module significance and there were various survival-associated genes (hub genes) in this module ([Fig. 6](#f6-mmr-16-05-6499){ref-type="fig"}). These connections were also verified in the validation dataset.

### Recurrence-associated module analysis

All 431 genes in the Brown module were subject to a clustering analysis and it was revealed that there were 3 types of samples ([Fig. 7](#f7-mmr-16-05-6499){ref-type="fig"}). As presented in [Fig. 7](#f7-mmr-16-05-6499){ref-type="fig"}, certain G2 type samples were also observed in with G1 and G2 type samples, suggesting it may have a medium role for the connection between the G1 and G3 status. Additionally, the recurrence interval of G3 samples was short, accompanied with downregulated genes.

The top 10 genes were collagen type VI α 3 chain (COL6A3), EGF containing fibulin like extracellular matrix protein 2 (EFEMP2), fibrillin 1 (FBN1), follistatin-like 1 (FSTL1), glycosyltransferase 8 domain containing 2 (GLT8D2), heart development protein with EGF like domains 1 (HEG1), RAB31, member RAS oncogene family (RAB31), secreted protein acidic and cysteine rich (SPARC), SPARC/osteonectin, cwcv and kazal like domains proteoglycan 1 (SPOCK1) and TIMP metallopeptidase inhibitor 2 (TIMP2) in the Brown module with higher degrees were associated with survival ([Table III](#tIII-mmr-16-05-6499){ref-type="table"}). Genes in the Brown module were primarily enriched in tumor recurrence-associated functions and pathways, including cell adhesion, biological adhesion, ECM organism, the ECM-receptor interaction and the focal adhesion pathways ([Table IV](#tIV-mmr-16-05-6499){ref-type="table"}).

### Validation of recurrence related modules

As presented in the KM curves ([Fig. 8](#f8-mmr-16-05-6499){ref-type="fig"}), there was a significant difference in terms of recurrence status (P=1.5×10^−6^) among the samples with high, median, and low gene expression level of the Brown module. High expression levels inidcated higher incidence of recurrence, whereas low expression levels show lower recurrence incidence. This association between gene expression level and recurrence incidence was validated in the dataset of E-GEOD-33113 (P=2.8×10^−2^).

Discussion
==========

Classification of the colon samples was downloaded from ArrayExpress revealed that there were significant differences of survival status and clinical data among the 3 subtype samples. From the 434 DEGs, SERP2 and LINC0129 were the common DEGs of the 3 subgroups, suggesting they may have an important role in the recurrence of colon cancer. The Brown module was the recurrence-associated module in the co-expression network of DEGs and the top 10 genes (COL6A3, EFEMP2, FBN1, FSTL1, GLT8D2, HEG1, RAB31, SPARC, SPOCK1, and TIMP2) in this module with higher degrees were demonstrated to be significantly associated with survival. Enrichment analysis revealed that genes in the Brown module were primarily enriched in tumor recurrence-associated functions and pathways, including cell and biological adhesion, ECM organization, the ECM-receptor interaction, and the focal adhesion pathways. Additionally, the association between the module and tumor recurrence were verified in another dataset E-GEOD-33113.

SERP2 belongs to the serine proteinase inhibitor family, which are key regulators for the biological pathways that initiate coagulation, inflammation, angiogenesis, apoptosis, complement activation response and ECM composition ([@b14-mmr-16-05-6499]). SERP2 methylation was identified to be a marker for the detection and diagnosis of colon cancer ([@b15-mmr-16-05-6499]). Expression of SERP2 is reported to be an early event in colon cancer, and is associated with carcinogenesis and its development ([@b16-mmr-16-05-6499]). LINC0129 is a long non-coding RNA (lincRNA) and lincRNAs are RNAs \>200 nt, which are not translated into proteins. Dysfunctions of lincRNAs have been associated with cancer. A previous study revealed that the downregulation of lincRNA BRAF-activated non-protein coding RNA may promote the proliferation of colorectal cancer cells ([@b17-mmr-16-05-6499]). Another previous study reported that lincRNA HOX transcript antisense RNA expression may be a poor prognosis indicator in colon cancer ([@b18-mmr-16-05-6499]). Additionally, overexpression of lincRNA prostate cancer associated transcript 1 was identified to be a novel biomarker of poor prognosis in patients with colon cancer ([@b19-mmr-16-05-6499]). However, there are currently no direct findings that have determined the connection between LINC0129 and colon cancer, all aforementioned findings may have suggested that it may have an important role in colorectal cancer by contributing to the process of relapse.

EFEMP2 is a serum biomarker for the early detection of colon cancer ([@b20-mmr-16-05-6499]) and a superior biomarker compared with carcinoembryonic-antigen, which is the sole biomarker currently used for the diagnosis and treatment monitor in colon cancer ([@b21-mmr-16-05-6499]). FBN1 is a component of the extracellular microfibril and the hypermethylation status of its promoter is a specific and sensitive biomarker for colon cancer ([@b22-mmr-16-05-6499]). SPARC is a matricellular protein involved in cell migration, angiogenesis and tissue remodeling. High SPARC expression may be associated with an improved clinical outcome in stage II colon cancer ([@b23-mmr-16-05-6499]). A previous study determined that the absence of stromal SPARC is an independent prognostic predicator for poor prognosis of colon cancer ([@b24-mmr-16-05-6499]). The high degrees of these genes in the recurrence-associated modules indicated that they have important roles in colon cancer relapse. Among the significantly enriched pathways, the ECM-receptor interaction and focal adhesion pathways were functionally clearly associated with the progression and prognosis of colon cancer ([@b25-mmr-16-05-6499]).

By constructing the co-expression network of genes and identifying the recurrence related modules in the network, the present study identified several survival and recurrence-associated genes in colon cancer. These genes, including SERP2, EFEMP2, FBN1, SPARC, and LINC0219 were identified as recurrence-associated molecular and prognosis indicators in colon cancer.

The present study was supported by the Shanghai Municipal Commission of Health and Family Planning (grant no. ZYSNXD-CC-ZDYJ032), the Fund from Shanghai Science and Technology Committee (grant no. 12401907800) and the Shanghai Science and Technology Committee (grant no 15401931700).
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###### 

Parameters used in sample classification using consensus clustering.

  Parameter            Value
  -------------------- --------------
  Max cluster group    20
  Subsample number     5,000
  Proportion sample    0.9
  Proportion feature   1
  Distance method      Pearson
  Clustering method    K-means dist

###### 

Association analysis on clinical data with sub-samples groups.

  Characteristic   χ^2^      df   P-value
  ---------------- --------- ---- -------------
  Sex              1.1653    2    5.58×10^−1^
  CGH data         17.0540   2    1.98×10^−4^
  Chemotherapy     19.7370   4    5.63×10^−4^
  MMR status       23.4140   4    1.05×10^−4^
  TNM stage        26.2990   8    9.34×10^−4^
  Tumor location   14.7690   2    6.21×10^−4^

MMR, mismatch repair; TNM, tumor node metastasis; CGH, comparative genomic hybridization; df, degrees of freedom.

###### 

Top 10 genes with high degrees in Brown module.

  Gene name   Coefficient   P-value      k total   k within
  ----------- ------------- ------------ --------- ----------
  *COL6A3*    2.17×10^−4^   1.9×10^−6^   136.82    91.86
  *EFEMP2*    2.10×10^−3^   9.2×10^−7^   172.24    110.00
  *FBN1*      1.42×10^−3^   5.7×10^−7^   137.03    92.14
  *FSTL1*     1.50×10^−3^   5.4×10^−7^   143.42    91.08
  *GLT8D2*    2.91×10^−3^   7.5×10^−7^   137.54    91.21
  *HEG1*      2.17×10^−3^   2.3×10^−5^   168.71    94.84
  *RAB31*     5.27×10^−4^   5.9×10^−5^   138.09    93.74
  *SPARC*     3.06×10^−4^   9.8×10^−8^   132.03    95.57
  *SPOCK1*    1.49×10^−3^   9.7×10^−7^   128.75    88.57
  *TIMP2*     5.34×10^−4^   4.2×10^−7^   166.30    105.73

###### 

Significantly enriched functional terms of genes in Brown module.

  Term ID      Function                                           Count   P-value
  ------------ -------------------------------------------------- ------- --------------
  GO:0007155   Cell adhesion                                      84      7.29×10^−36^
  GO:0022610   Biological adhesion                                84      8.12×10^−36^
  GO:0030198   Extracellular matrix organization                  30      2.31×10^−23^
  GO:0043062   Extracellular structure organization               32      1.46×10^−19^
  GO:0001501   Skeletal system development                        40      2.50×10^−17^
  GO:0001944   Vasculature development                            35      1.35×10^−16^
  GO:0001568   Blood vessel development                           34      5.71×10^−16^
  GO:0009611   Response to wounding                               45      3.90×10^−13^
  GO:0006928   Cell motion                                        40      1.36×10^−11^
  GO:0042060   Wound healing                                      25      2.72×10^−11^
  GO:0016477   Cell migration                                     28      5.08×10^−10^
  GO:0048870   Cell motility                                      29      1.19×10^−9^
  GO:0051674   Localization of cell                               29      1.19×10^−9^
  GO:0048514   Blood vessel morphogenesis                         24      1.25×10^−9^
  GO:0051270   Regulation of cell motion                          22      6.93×10^−9^
  GO:0035295   Tube development                                   23      1.44×10^−8^
  GO:0030334   Regulation of cell migration                       20      2.15×10^−8^
  GO:0040012   Regulation of locomotion                           21      3.35×10^−8^
  GO:0042127   Regulation of cell proliferation                   45      1.12×10^−7^
  GO:0016337   Cell-cell adhesion                                 22      2.97×10^−6^
  GO:0007167   Enzyme linked receptor protein signaling pathway   23      2.49×10^−5^
  GO:0010033   Response to organic substance                      36      5.15×10^−5^
  GO:0008285   Negative regulation of cell proliferation          23      5.67×10^−5^
  GO:0006954   Inflammatory response                              21      1.07×10^−4^
  GO:0000902   Cell morphogenesis                                 22      1.32×10^−4^
  GO:0032989   Cellular component morphogenesis                   23      2.24×10^−4^
  GO:0008284   Positive regulation of cell proliferation          23      3.97×10^−4^
  GO:0030182   Neuron differentiation                             23      8.49×10^−4^
  hsa04512     ECM-receptor interaction                           26      1.80×10^−21^
  hsa04510     Focal adhesion                                     35      1.85×10^−20^
  hsa05200     Pathways in cancer                                 22      3.45×10^−5^
  hsa04060     Cytokine-cytokine receptor interaction             15      4.34×10^−3^
  hsa04810     Regulation of actin cytoskeleton                   13      5.83×10^−3^

GO, gene ontology.

[^1]: Contributed equally
